基因總覽
STAT3（signal transducer and activator of transcription 3）是蛋白質編碼基因，產物屬於 STAT 轉錄因子家族。其名稱反映了訊號轉導與轉錄活化兩種角色：STAT3 能接收細胞外訊號，並參與調控目標基因的表現。來源所述的刺激包括多種 interleukins、KITLG/SCF、LEP 與其他生長因子；在不同訊號條件下，STAT3可參與不同細胞反應。蛋白質具有 SH2 domain，另有一段被註記為核輸入所必需的序列區域。這些特徵提供了理解其訊號反應與轉錄調控角色的基本背景；具體的活化方式及其下游生物學作用如下方功能說明。
基因異名與舊稱
異名取自 HGNC，可能包含歷史名稱；蛋白質名稱以 UniProt 註解為準。
染色體位置與基因結構
查看實際轉錄本與 exon 註解
| Transcript | Genomic coordinates | Exons |
|---|---|---|
| ENST00000264657 ★ | 42,313,324–42,388,442 | 24 |
| ENST00000678960 | 42,313,324–42,388,568 | 25 |
| ENST00000678906 | 42,313,324–42,388,454 | 25 |
| ENST00000715205 | 42,313,324–42,388,568 | 24 |
| ENST00000677421 | 42,313,324–42,388,568 | 23 |
| ENST00000678048 | 42,313,324–42,388,568 | 23 |
| ENST00000678674 | 42,313,324–42,388,568 | 23 |
| ENST00000678913 | 42,313,324–42,388,568 | 24 |
| ENST00000678792 | 42,313,324–42,388,568 | 24 |
| ENST00000679166 | 42,313,324–42,388,568 | 23 |
| ENST00000677442 | 42,313,324–42,388,568 | 24 |
| ENST00000677723 | 42,313,324–42,388,568 | 24 |
顯示 12/80 個蛋白質編碼轉錄本；canonical 優先。
帶型與著絲點依 Ensembl 座標繪製；核染色體長度以 GRCh38 第 1 號染色體為共同尺度。黃色標記表示本基因位置，細小區間加粗以利辨識；實際基因長度與 exon 見下方資料。
分子功能與生物學過程
STAT3 會介導細胞對多種細胞激素與生長因子的反應。訊號活化後，它可招募 NCOA1 或 MED1 等共活化因子至目標基因啟動子區域，參與轉錄調控。IL6 活化 IL6ST/gp130 訊號時，STAT3 會結合多種急性期蛋白基因啟動子中的 IL6-responsive elements；IL31 則可透過 IL31RA 活化 STAT3。STAT3 也可能介導活化型 FGFR1、FGFR2、FGFR3 與 FGFR4 所引發的細胞反應，並參與 oncostatin-M 經由兩類受體複合體傳遞的訊號。
在免疫調節方面，STAT3 參與調控初始 CD4(+) T 細胞分化為 T-helper Th17 或 regulatory T-cells（Treg），因而與發炎反應調節相關。其轉錄活性受修飾狀態影響：乙醯化可促進轉錄活性及細胞分化；相對地，去乙醯化以及 LOXL3 對 lysine residues 的氧化會抑制分化。這些作用說明 STAT3 的免疫調節功能受細胞內調控條件影響。
STAT3 亦參與細胞週期調節，可誘導促進 G1 期進入 S 期的關鍵基因表現，例如 CCND1。在其他生理情境中，依相似性推定，它介導 LEP 對 melanocortin 產生、身體能量恆定與泌乳的影響；在 LEP 活化時，也可能藉由促進 BIRC5 表現而參與細胞凋亡。細胞質中的 STAT3 則可抑制 EIF2AK2/PKR 活性，進而抑制 macroautophagy。
STAT3 也與特定細胞功能及轉錄複合體相關。依相似性推定，它對胰島 beta 細胞的基礎功能（包括胰島素分泌調節）具有重要作用。在 cardiomyocytes 中，JAK/STAT 訊號活化後，STAT3 與 NFATC3、NFATC4 形成複合體，結合 CRYAB 的 alpha-beta E4 promoter region 並活化轉錄。這些不同作用顯示，STAT3 的生物學影響會隨訊號來源、細胞環境與其所在位置而異。
Promoter 與基因調控
>STAT3 ENST00000264657 GRCh38 chr17:42388342-42389442 strand=-1 5′→3′ 相對 TSS：-1000 到 +100 bp；1101 bp 依轉錄本 TSS 擷取的基因組序列；TSS = 0，兩端包含，未驗證為 promoter ATCACTCCATTATGCAAAGTTCATCCTCTATTATGAAAGGCAAAATGTCTACATTTCCTATCAACCACTG GCTTCAATTCAGTAAAACTTGCATACCAAGTAGGCAAGGTGGAAAAGAAAAAGGCAGAACATTTCATGTA TTTCAATTCAGACGCATAAAAATGTCAAGCCCTACACGTTATCAGCTTTCGTATACACCGTCTTCTGCAT TCGCCTGTACGGGCCAATGGGCTAGCTGGTCGGCGTTTGATGCTTGAAGTGATGGAACGGAGTACGGGGT TAAATCCACTACCCTCTCCCCACGCACTCTAGTAATTACTCTATTTCCACGTCATGTTTCCGGGTGTGTG TGTCCCTGCTCACGCAGAAACTGAAGTTCAAAGCAGGCGGAGTCACCCATGTTCTTTTTGTTGTCCCCAG AACCCAATTCAGGAGTTGGGTCCCCAGAGGATCTGGAGATACCTGGGGACTATCTAACTAGCTGATTCCC GCGTGGTAAGAGGCTCTCAACCTCGCCACCACGTGGTGCCAAGGGCCGGGAAAAGGGAGAGCGGGCAGGA GGGAGCTGTATCAGGGGCATTTAAAGTGCCTTGACGTCACGCACTGCCAGGAACTCAGCTGAGTTTTCAG CAGGACATTCCGGTCATCTTCCCTCCCTCCCCCCGGGCTTCTGTGCCCAAGTCCTCGGCTCTTCCCTCGC TGTGGCGGAGGGAGGAGCACCGAACTGTCGGAACAGCCAGCACAGGGGCGTATCAGTCTCCTCTTGGCTC CGCCCTTTCTCCTAGCTGCTCTCCTCATTGGTCAGTGGGCGGGGCTTCGGCTGTACCGCACACGCACTGG GACCTCTGGGTGGCCGAACGAGCTGGCCTTTCATGAATTATGCATGACGGCGTGCCTCGGCCAGGCTGGG GCTGGGCGAGGATTGGCTGAAGGGGCTGTAATTCAGCGGTTTCCGGAGCTGCGGCGGCGCAGACTGGGAG GGGGAGCCGGGGGTTCCGACGTCGCAGCCGAGGGAACAAGCCCCAACCGGATCCTGGACAGGCACCCCGG CTTGGCGCTGTCTCTCCCCCTCGGCTCGGAGAGGCCCTTCGGCCTGAGGGA
EPDnew 實驗支持 promoter／TSS · 1 筆
| EPDnew ID | TSS（1-based） | 股向 | 來源顯示區間 |
|---|---|---|---|
| STAT3_1 ↗ | 17:42,388,442 | 負股 | 42,388,432–42,388,491 |
EPDnew human v006 · UCSC hg38，GRCh38/hg38，透過 UCSC 取得。TSS 具有 CAGE／RAMPAGE 等實驗資料支持；任意擷取的上下游區間仍需另行判讀調控功能，不能視為整段皆經功能驗證。
EPD 封存狀態 ↗ · UCSC 資料說明 ↗ · EPD team, SIB Swiss Institute of Bioinformatics; UCSC Genome Browser · CC BY 4.0
查看已取得的調控／motif 註解
ENSR17_C67K8 · enhancer · 42386819–42388362 · regulatory
ENSR17_9LS98 · promoter · 42388363–42388861 · regulatory
ENSR17_BBF5N · enhancer · 42388862–42389541 · regulatory
ENSR17_5CZ7C2 · CTCF_binding_site · 42388913–42388934 · regulatory
ENSR17_9LS9L · enhancer · 42389760–42390229 · regulatory
· motif · 42385073–42385088 · motif
· motif · 42385073–42385088 · motif
· motif · 42385410–42385422 · motif
· motif · 42386927–42386938 · motif
· motif · 42386931–42386945 · motif
· motif · 42387063–42387077 · motif
· motif · 42387063–42387077 · motif
· motif · 42387357–42387377 · motif
· motif · 42388312–42388323 · motif
· motif · 42388628–42388638 · motif
· motif · 42388689–42388699 · motif
· motif · 42388780–42388790 · motif
· motif · 42388832–42388848 · motif
· motif · 42388841–42388854 · motif
· motif · 42388841–42388854 · motif
· motif · 42388915–42388931 · motif
· motif · 42388916–42388925 · motif
· motif · 42388916–42388925 · motif
· motif · 42388972–42388985 · motif
· motif · 42388991–42389004 · motif
· motif · 42388991–42389004 · motif
· motif · 42389097–42389108 · motif
· motif · 42391428–42391442 · motif
· motif · 42391626–42391637 · motif
· motif · 42392503–42392514 · motif
· motif · 42393230–42393239 · motif
· motif · 42393230–42393239 · motif
· motif · 42393406–42393428 · motif
· motif · 42393406–42393428 · motif
蛋白質結構域與序列
參考蛋白質長度：770 aa
STAT3 蛋白質長 770 個胺基酸，屬於 STAT 轉錄因子家族。其 SH2 domain 位於第 580–670 個胺基酸；第 150–162 個胺基酸區段則註記為核輸入所必需。這些是來源列出的結構與序列特徵。
蛋白質三維結構
細胞內定位
沒有刺激時，STAT3 主要位於細胞質，但也可在細胞核與細胞質間穿梭；部分情況下，其持續存在於細胞核不依賴 tyrosine phosphorylation。 活化型 FGFR 訊號引發 tyrosine phosphorylation 與二聚化後，STAT3 會轉位至細胞核；LIF 刺激也會促使其在細胞核累積。
深綠色圓點：來源記載的蛋白質定位；數量不表示含量。
動物細胞結構示意；器官大小與數量不按比例。點選細胞構造可查看定位註解。
交互作用與訊號網絡
拖曳節點後放開可帶動位置變化；點選夥伴查看證據。位置與連線長度不代表結合強度，圖中未推定夥伴彼此之間的關係。
更多交互作用夥伴 · 已取得 56 個夥伴
- BCKDKO14874 · UniProt INTERACTION · 2 experiments
- BICD1Q96G01 · UniProt INTERACTION · 2 experiments
- BLKP51451 · UniProt INTERACTION · 9 experiments
- BMXP51813 · UniProt INTERACTION · 8 experiments
- CAPN1P07384 · UniProt INTERACTION · 2 experiments
- CCT3P49368 · UniProt INTERACTION · 2 experiments
- CDK9P50750 · UniProt INTERACTION · 2 experiments
- CORO1AP31146 · UniProt INTERACTION · 2 experiments
- CSF3RQ99062 · UniProt INTERACTION · 4 experiments
- DAXXQ9UER7 · UniProt INTERACTION · 4 experiments
- DIRAS3O95661 · UniProt INTERACTION · 3 experiments
- ECH1Q13011 · UniProt INTERACTION · 2 experiments
- ECHS1P30084 · UniProt INTERACTION · 3 experiments
- EGFRP00533 · UniProt INTERACTION · 16 experiments
- ERBB2P04626 · UniProt INTERACTION · 9 experiments
- EZH2Q15910 · UniProt INTERACTION · 5 experiments
- FHL2Q14192 · UniProt INTERACTION · 3 experiments
- GADD45GIP1Q8TAE8 · UniProt INTERACTION · 4 experiments
- GNL3Q9BVP2 · UniProt INTERACTION · 2 experiments
- IMPDH2P12268 · UniProt INTERACTION · 4 experiments
- ITPR3Q14573 · UniProt INTERACTION · 10 experiments
- JAK1P23458 · UniProt INTERACTION · 3 experiments
- KHDRBS1Q07666 · UniProt INTERACTION · 2 experiments
- LASP1Q14847 · UniProt INTERACTION · 4 experiments
- LMO2P25791 · UniProt INTERACTION · 3 experiments
STAT3 可形成同源二聚體，也可與相關家族成員（至少包括 STAT1）形成異源二聚體；它亦是由 STAT3、NFATC3 與 NFATC4 組成的 promoter-binding complex 成員，calcineurin 可增強複合體形成。另有多種條件性或直接互作，例如 STAT3 與 IL23R 在 IL23 存在時互作，而 PIAS3 在 IL6、CNTF 或 OSM 刺激下與 STAT3 互作並抑制其 DNA 結合活性。感染情境下，STAT3 也與 HCV core protein 及 S.typhimurium SarA 互作；人類 cytomegalovirus（HHV-5）IE1 的互作則與 STAT3 核內累積及 IL6 引發的 STAT3 磷酸化受干擾有關。
疾病與遺傳關聯
STAT3 相關基因變異與兩種疾病有關。Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections 是罕見的免疫與結締組織疾病，特徵包括免疫缺陷、慢性嗜酸性球增多、特殊粗獷面容、牙齒異常、關節過度伸展及骨折。Autoimmune disease, multisystem, infantile-onset, 1 則在幼年發病，可影響多個器官，表現包括胰島素依賴型糖尿病、自體免疫性腸病或乳糜瀉；亦可能伴隨身材矮小、非特異性皮膚炎、甲狀腺功能低下、自體免疫性關節炎及青春期延遲。來源指出兩者均由影響 STAT3 基因的變異造成。
Contextual Functional Evidence Matrix
矩陣以「功能主張」為列，以細胞情境、干預條件、量測結果與證據來源為欄，方便比較同一功能在不同條件下的支持情形。只有含情境與實驗資訊的紀錄會列入矩陣；一般功能註解另列於下方。
功能註解總覽 · 8 筆
| 功能面向 | 功能敘述 | 證據類型 | 可查核來源 |
|---|---|---|---|
| 功能 | STAT3 是介導細胞對 interleukins、KITLG/SCF、LEP 與其他生長因子反應的訊號轉導及轉錄活化因子。活化後可招募 NCOA1 或 MED1 至目標基因啟動子；也參與 IL6、IL31、FGFR 與 oncostatin-M 訊號。其功能涵蓋 T 細胞分化與發炎調節、細胞週期、macroautophagy，以及依相似性推定的能量恆定、泌乳與胰島 beta 細胞功能。 | 含實驗來源 | 證據與來源Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Upon activation of IL6ST/gp130 signaling by interleukin-6 (IL6), binds to the IL6-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation promotes its transcription activity and cell differentiation while deacetylation and oxidation of lysine residues by LOXL3 inhibits differentiation. Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1. Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transactivating BIRC5 expression under LEP activation. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity). Following JAK/STAT signaling activation and as part of a complex with NFATC3 and NFATC4, binds to the alpha-beta E4 promoter region of CRYAB and activates transcription in cardiomyocytes (By similarity). Involved in the oncostatin-M-mediated signaling pathway through both type I OSM receptor complex (heterodimers composed of LIFR and IL6ST) and type II OSM receptor complex (heterodimers composed of OSMR and IL6ST) PMID 10688651 ↗ · PMID 11294841 ↗ · PMID 12359225 ↗ · PMID 12873986 ↗ · PMID 15194700 ↗ · PMID 15653507 ↗ · PMID 16285960 ↗ · PMID 17344214 ↗ · PMID 18242580 ↗ · PMID 18782771 ↗ · PMID 22306293 ↗ · PMID 23084476 ↗ · PMID 28065600 ↗ · PMID 28262505 ↗ · PMID 32929201 ↗ · PMID 38404237 ↗ · PMID 9188471 ↗ |
| 交互作用 | STAT3 可形成同源二聚體，或與至少 STAT1 形成異源二聚體，也可和 NFATC3、NFATC4 組成 promoter-binding complex，且 calcineurin 會增強複合體形成。它與多種蛋白質互作，部分互作受刺激或修飾狀態影響；例如 IL23 存在時與 IL23R 互作，受 IL6、CNTF 或 OSM 刺激時與 PIAS3 互作並抑制 DNA 結合活性。FAM220A 與 PTPN2 相關互作可促進 STAT3 去磷酸化，負向調節其轉錄活性。 | 含實驗來源 | 證據與來源Forms a homodimer or a heterodimer with a related family member (at least STAT1). Component of a promoter-binding complex composed of STAT3, NFATC3 and NFATC4; complex formation is enhanced by calcineurin (By similarity). Interacts with IL31RA, NCOA1, PELP1, SIPAR, SOCS7, STATIP1 and TMF1 (By similarity). Interacts with IL23R in presence of IL23. Interacts (via SH2 domain) with NLK. Interacts with ARL2BP; the interaction is enhanced by LIF and JAK1 expression (By similarity). Interacts with KPNA4 and KPNA5; KPNA4 may be the primary mediator of nuclear import (By similarity). Interacts with CAV2; the interaction is increased on insulin-induced tyrosine phosphorylation of CAV2 and leads to STAT3 activation (By similarity). Interacts with ARL2BP; interaction is enhanced with ARL2. Interacts with NEK6 (By similarity). Binds to CDK9 when activated and nuclear. Interacts with BMX. Interacts with ZIPK/DAPK3. Interacts with PIAS3; the interaction occurs on stimulation by IL6, CNTF or OSM and inhibits the DNA binding activity of STAT3. In prostate cancer cells, interacts with PRKCE and promotes DNA binding activity of STAT3. Interacts with STMN3, antagonizing its microtubule-destabilizing activity (By similarity). Interacts with the 'Lys-129' acetylated form of BIRC5/survivin. Interacts with FER. Interacts (via SH2 domain) with EIF2AK2/PKR (via the kinase catalytic domain). Interacts with INPP5F; the interaction is independent of STAT3 Tyr-705 phosphorylation status. Interacts with FGFR4. Interacts with OCIAD1 (By similarity). Interacts with OCIAD2. Interacts (unphosphorylated or phosphorylated at Ser-727) with PHB1. Interacts and may form heterodimers with NHLH1 (By similarity). Found in a complex with SLC39A6, SLC39A10 and with the 'Ser-727' phosphorylated form of STAT3 throughout mitosis. Interacts (when phosphorylated at Tyr-705) with CD274/PD-L1; promoting nuclear translocation of CD274/PD-L1. Interacts (when acetylated) with EP300 (via bromo domain); interaction takes place following STAT3 acetylation by EP300 and promotes enhanceosome assembly. Interacts (when acetylated) with BRD2 (via bromo domain); interaction promotes STAT3 recruitment to chromatin and T-helper Th17 cell differentiation. Interacts with FAM220A/SIPAR; the interaction occurs in both the nucleus and the cytoplasm, is enhanced by IL6 and promotes STAT3 dephosphorylation (By similarity). Interacts in both unphosphorylated and phosphorylated forms with FAM220A but interacts preferentially in the phosphorylated form in the nucleus (By similarity). Interacts with PTPN2; the interaction is promoted by FAM220A and leads to STAT3 dephosphorylation which negatively regulates STAT3 transcriptional activator activity (By similarity) PMID 10688651 ↗ · PMID 11773079 ↗ · PMID 12023369 ↗ · PMID 12873986 ↗ · PMID 15194700 ↗ · PMID 15467733 ↗ · PMID 15653507 ↗ · PMID 15677474 ↗ · PMID 15994929 ↗ · PMID 16219639 ↗ · PMID 17344214 ↗ · PMID 17875724 ↗ · PMID 17956865 ↗ · PMID 18070987 ↗ · PMID 18234692 ↗ · PMID 18782771 ↗ · PMID 19147545 ↗ · PMID 20826784 ↗ · PMID 23084476 ↗ · PMID 25476455 ↗ · PMID 26675719 ↗ · PMID 28065600 ↗ · PMID 28262505 ↗ · PMID 29743632 ↗ · PMID 31899195 ↗ · PMID 32797246 ↗ · PMID 32929201 ↗ · PMID 9388184 ↗ |
| 交互作用 | 在微生物感染情境下，STAT3 與 HCV core protein 互作。 | 含實驗來源 | |
| 交互作用 | 在微生物感染情境下，STAT3 與 S.typhimurium SarA 互作。 | 含實驗來源 | |
| 交互作用 | 在感染情境下，STAT3 與 human cytomegalovirus（HHV-5）的 immediate early protein IE1 互作。此互作會導致 STAT3 在細胞核累積，並干擾 IL6 誘導的 STAT3 磷酸化。 | 含實驗來源 | 證據與來源(Microbial infection) Interacts with human cytomegalovirus (HHV-5) immediate early protein IE1; this interaction leads to STAT3 nuclear accumulation and disruption of IL6-induced STAT3 phosphorylation PMID 27387064 ↗ |
| 細胞定位 | STAT3 位於細胞質與細胞核之間並可往返；無刺激時主要在細胞質。活化型 FGFR 訊號造成 tyrosine phosphorylation 與二聚化後可促使其進入細胞核，但持續存在於細胞核也可能不依賴 tyrosine phosphorylation。LIF 刺激、EDN1 存在時亦可促使核轉位；BART 與 ARL2 複合體參與其核輸入及滯留。 | 含實驗來源 | 證據與來源Cytoplasm; Nucleus; Shuttles between the nucleus and the cytoplasm. Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4. Constitutive nuclear presence is independent of tyrosine phosphorylation. Predominantly present in the cytoplasm without stimuli. Upon leukemia inhibitory factor (LIF) stimulation, accumulates in the nucleus. The complex composed of BART and ARL2 plays an important role in the nuclear translocation and retention of STAT3. Identified in a complex with LYN and PAG1. Translocates to the nucleus in the presence of EDN1 (By similarity) PMID 15653507 ↗ · PMID 16285960 ↗ · PMID 28065600 ↗ · PMID 31899195 ↗ · PMID 41219491 ↗ · PMID 29162862 ↗ |
| 疾病關聯 | Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections 是一種罕見的免疫與結締組織疾病，特徵包括免疫缺陷、慢性嗜酸性球增多、特殊粗獷面容、牙齒異常、關節過度伸展及骨折。此疾病由影響 STAT3 基因的變異造成。 | 含實驗來源 | 證據與來源Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections HIES1 A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures. The disease is caused by variants affecting the gene represented in this entry MIM: 147060 PMID 17676033 ↗ · PMID 17881745 ↗ · PMID 23342295 ↗ · PMID 26293184 ↗ |
| 疾病關聯 | Autoimmune disease, multisystem, infantile-onset, 1 在幼年早期發病，涉及多器官的自體免疫表現，包括胰島素依賴型糖尿病、自體免疫性腸病或乳糜瀉；其他特徵可包括身材矮小、非特異性皮膚炎、甲狀腺功能低下、自體免疫性關節炎及青春期延遲。此疾病由影響 STAT3 基因的變異造成。 | 含實驗來源 | 證據與來源Autoimmune disease, multisystem, infantile-onset, 1 ADMIO1 A disorder characterized by early childhood onset of a spectrum of autoimmune manifestations affecting multiple organs, including insulin-dependent diabetes mellitus and autoimmune enteropathy or celiac disease. Other features include short stature, non-specific dermatitis, hypothyroidism, autoimmune arthritis, and delayed puberty. The disease is caused by variants affecting the gene represented in this entry MIM: 615952 PMID 25038750 ↗ · PMID 25359994 ↗ · PMID 28073828 ↗ · PMID 28253502 ↗ · PMID 28579554 ↗ · PMID 29162862 ↗ · PMID 36228738 ↗ · PMID 38404237 ↗ |
核酸與蛋白質序列
GTCGCAGCCGAGGGAACAAGCCCCAACCGGATCCTGGACA40GGCACCCCGGCTTGGCGCTGTCTCTCCCCCTCGGCTCGGA80GAGGCCCTTCGGCCTGAGGGAGCCTCGCCGCCCGTCCCCG120GCACACGCGCAGCCCCGGCCTCTCGGCCTCTGCCGGAGAA160ACAGTTGGGACCCCTGATTTTAGCAGGATGGCCCAATGGA200ATCAGCTACAGCAGCTTGACACACGGTACCTGGAGCAGCT240CCATCAGCTCTACAGTGACAGCTTCCCAATGGAGCTGCGG280CAGTTTCTGGCCCCTTGGATTGAGAGTCAAGATTGGGCAT320ATGCGGCCAGCAAAGAATCACATGCCACTTTGGTGTTTCA360TAATCTCCTGGGAGAGATTGACCAGCAGTATAGCCGCTTC400CTGCAAGAGTCGAATGTTCTCTATCAGCACAATCTACGAA440GAATCAAGCAGTTTCTTCAGAGCAGGTATCTTGAGAAGCC480AATGGAGATTGCCCGGATTGTGGCCCGGTGCCTGTGGGAA520GAATCACGCCTTCTACAGACTGCAGCCACTGCGGCCCAGC560AAGGGGGCCAGGCCAACCACCCCACAGCAGCCGTGGTGAC600GGAGAAGCAGCAGATGCTGGAGCAGCACCTTCAGGATGTC640CGGAAGAGAGTGCAGGATCTAGAACAGAAAATGAAAGTGG680TAGAGAATCTCCAGGATGACTTTGATTTCAACTATAAAAC720CCTCAAGAGTCAAGGAGACATGCAAGATCTGAATGGAAAC760AACCAGTCAGTGACCAGGCAGAAGATGCAGCAGCTGGAAC800AGATGCTCACTGCGCTGGACCAGATGCGGAGAAGCATCGT840GAGTGAGCTGGCGGGGCTTTTGTCAGCGATGGAGTACGTG880CAGAAAACTCTCACGGACGAGGAGCTGGCTGACTGGAAGA920GGCGGCAACAGATTGCCTGCATTGGAGGCCCGCCCAACAT960cDNA 使用 DNA 字母 T；mRNA 模式改以 U 顯示。轉錄本保留已註解的非編碼區，未另外加入 poly(A) 尾；非編碼 RNA 的參考轉錄本也可能仍需後續加工。數字為所選序列的 1-based 位置。長序列以黃色捲軸瀏覽，可複製或下載完整轉錄本與蛋白質；基因組 DNA 隨捲動取得所需範圍。